The XYF19 CAR-T cell therapy targets CD19, a well-established antigen in B cell malignancies, and employs CRISPR technology to enhance therapeutic efficacy by eliminating endogenous HPK1. This first-in-human trial is positioned in a competitive landscape dominated by existing CAR-T therapies, particularly those targeting CD19, such as Kymriah and Yescarta. The trial's focus on relapsed or refractory cases, particularly in patients not eligible for HSCT, addresses a significant unmet medical need. Successful outcomes could position Xijing Hospital and its collaborator, Xi'An Yufan Biotechnology Co., Ltd, favorably in the CAR-T market, which is projected to grow significantly, driven by increasing incidences of hematological malignancies and advancements in gene editing technologies.